Chair: Shomik Sengupta
Discussant: Jon Emery
Discussant: Jon Emery
Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) + dacarbazine (DTIC) on phase 3 study CA184-024 (#711)
3:15 PM
Is there a survival benefit in the receipt of guideline recommended therapy in non metastatic non small cell lung cancer? (#712)
3:20 PM
βIII-tubulin and glioblastoma: Role in drug resistance and tumourigenesis (#713)
3:25 PM
Mechanism of IGF induced epithelial-to-mesenchymal transition (EMT) in melanoma progression (#714)
3:30 PM
Breast cancer diagnosis and patterns of treatment: does being Indigenous make a difference? (#715)
3:35 PM